Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 in IDH1 Mutant Chondrosarcoma
NCT04278781Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2020
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib in chondrosarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 16 weeks. Started Mar 2020; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NCT04278781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278781.